News Anthropic puts life sciences at heart of new AI model Anthropic has released Claude Fable 5, trumpeting its R&D credentials, but has faced a backlash over "safeguards" built into the model.
News Dyno attracts $1.6bn gene therapy deal with Astellas Astellas has signed another bolt-on deal to build its gene therapy pipeline, agreeing a deal with Dyno Therapeutics to tap into its adeno-associated virus (AAV) vector platform for deliveri
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.